Business Context and Reporting Period
Company: Shoulder Innovations, Inc. (SI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter ended March 31, 2026
Business Overview: A commercial-stage medical technology company focused on shoulder arthroplasty implant systems (InSet Glenoid and humeral stem products). The company operates as a single segment, selling primarily in the United States through a network of independent distributors and a dedicated commercial team. The company completed its IPO on August 1, 2025, and is classified as an emerging growth company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Revenue | $16.71 million | $10.13 million |
| Gross Profit | $12.99 million | $7.79 million |
| Gross Margin | 77.7% | 76.9% |
| Operating Loss | $(8.98) million | $(4.29) million |
| Net Loss | $(8.38) million | $(4.66) million |
| Adjusted EBITDA | $(6.96) million | $(3.50) million |
| Cash and Cash Equivalents | $11.49 million | $6.37 million (end of period) |
| Marketable Securities | $97.05 million | N/A (Not reported in Q1 2025 balance sheet) |
| Total Liquidity (Cash + Securities) | $108.54 million | N/A |
| Long-Term Debt | $14.96 million | N/A |
| Net Cash Used in Operating Activities | $(12.36) million | $(6.48) million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 64.9% year-over-year, driven by a 51.1% increase in implant systems sold (2,184 units in Q1 2026 vs. 1,443 in Q1 2025) and an increase in the number of customers. Average selling price rose to $7,650 from $7,022.
- Expense Expansion: Operating expenses increased 81.7% to $21.96 million.
- Selling, General & Administrative (SG&A): Increased 73.4% to $18.21 million, primarily due to higher personnel costs ($3.25M), commissions ($2.17M), and public company costs ($1.23M).
- Research & Development (R&D): Increased 137.1% to $3.75 million, largely driven by a $2.28M increase in external consulting fees related to a strategic partnership for a robotic platform.
- Interest Income: The company reported net interest income of $0.44 million in Q1 2026, compared to interest expense of $0.37 million in Q1 2025, due to higher yields on marketable securities.
- Cash Position: Cash and cash equivalents decreased by $15.38 million during the quarter, primarily due to operating cash outflows and net investing activities, despite strong revenue growth.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue incurring losses for the foreseeable future as it scales its commercial organization and invests in R&D. The company believes its current cash, cash equivalents, and marketable securities ($108.5 million) are sufficient to fund operations for at least 12 months.
- Strategic Initiatives:
- Continued investment in a shoulder-specific micro-robotic solution (announced December 2025).
- Expansion of product lines, including FDA clearance received in January 2026 for products for patients with metal sensitivity and additional fracture indications.
- Focus on Ambulatory Surgery Centers (ASCs) as a key growth driver following Medicare coverage changes effective January 2024.
- Capital Resources: The company has a $15.0 million term loan (Trinity Loan Agreement) with interest-only payments through September 2028. Two additional tranches of $15.0 million each were available but the second tranche expired in December 2025 without being drawn; the third tranche is available through December 2026 subject to revenue milestones.
- Risks and Contingencies:
- Litigation: Ongoing patent infringement lawsuit filed against Catalyst Orthoscience Inc. (with a counterclaim filed by Catalyst). The outcome is uncertain, and no accrual has been made as losses are not currently estimable.
- Related Party Transactions: Significant payments to Genesis Software (related to CEO/COO) for software licensing and development ($2.91M in Q1 2026).
- Seasonality: The company anticipates lower demand in the third calendar quarter due to summer seasonality.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $108.5 million liquidity position against the accelerating burn rate (operating cash burn of $12.36M in Q1).
- Debt Covenants: Confirm compliance with the Trinity Loan Agreement covenants, specifically the revenue milestones required to access the third tranche of funding.
- Litigation Exposure: Monitor the status of the Catalyst Orthoscience patent dispute for potential material adverse effects or settlement costs.
- R&D ROI: Assess the progress and commercial viability of the new robotic platform, which drove a 137% increase in R&D expenses.
- Related Party Costs: Review the ongoing royalty and development payments to Genesis Software to ensure they remain aligned with market rates and business needs.